Kif21b expression correlates with both AD and MS pathology. A) Kif21b expression was stratified for AD patients according to the Braak criteria. AD patients with more severe AD pathology (Braak stage 6) had significantly higher kif21b expression levels. B) For MS patients, the total area of grey matter demyelination was quantified and percentage of cortical demyelination was calculated. With increasing percentage of GM demyelination, enhanced kif21b expression was observed.